中华眼底病杂志
中華眼底病雜誌
중화안저병잡지
CHINESE JOURNAL OF OCULAR FUNDUS DISEASES
2001年
1期
24-25
,共2页
梅妍%袁天国%汪洁%杨峥嵘%秦琼莲%解松
梅妍%袁天國%汪潔%楊崢嶸%秦瓊蓮%解鬆
매연%원천국%왕길%양쟁영%진경련%해송
玻璃体视网膜病,增生性/药物疗法%组织型纤溶酶原激活物,组织型%三尖杉酯碱类/治疗应用%肝素/治疗应用
玻璃體視網膜病,增生性/藥物療法%組織型纖溶酶原激活物,組織型%三尖杉酯堿類/治療應用%肝素/治療應用
파리체시망막병,증생성/약물요법%조직형섬용매원격활물,조직형%삼첨삼지감류/치료응용%간소/치료응용
目的观察组织型纤溶酶原激活剂(tissue plasminogen activator,t-PA)、肝素和高三尖杉酯碱联合用药对术后增生性玻璃体视网膜病变(proliferative vitreoretinopathy,PVR)的抑制效果。方法 43例44只眼接受玻璃体视网膜手术的复杂性视网膜脱离患者,根据手术及是否同时球内联合用药分为A、B两组(A组为用药组,B组为对照组)。随访观察两组术后PVR再发生及视网膜脱离复发情况,平均随访期为7.9个月。结果 PVR发生率:A组15.8%,B组45.5%,χ2检验,P<0.05。视网膜脱离复发率A组5.5%,B组33.3%,χ2检验,P<0.05。结论手术辅以球内联合用药可有效抑制术后PVR再形成,降低视网膜脱离复发率。
目的觀察組織型纖溶酶原激活劑(tissue plasminogen activator,t-PA)、肝素和高三尖杉酯堿聯閤用藥對術後增生性玻璃體視網膜病變(proliferative vitreoretinopathy,PVR)的抑製效果。方法 43例44隻眼接受玻璃體視網膜手術的複雜性視網膜脫離患者,根據手術及是否同時毬內聯閤用藥分為A、B兩組(A組為用藥組,B組為對照組)。隨訪觀察兩組術後PVR再髮生及視網膜脫離複髮情況,平均隨訪期為7.9箇月。結果 PVR髮生率:A組15.8%,B組45.5%,χ2檢驗,P<0.05。視網膜脫離複髮率A組5.5%,B組33.3%,χ2檢驗,P<0.05。結論手術輔以毬內聯閤用藥可有效抑製術後PVR再形成,降低視網膜脫離複髮率。
목적관찰조직형섬용매원격활제(tissue plasminogen activator,t-PA)、간소화고삼첨삼지감연합용약대술후증생성파리체시망막병변(proliferative vitreoretinopathy,PVR)적억제효과。방법 43례44지안접수파리체시망막수술적복잡성시망막탈리환자,근거수술급시부동시구내연합용약분위A、B량조(A조위용약조,B조위대조조)。수방관찰량조술후PVR재발생급시망막탈리복발정황,평균수방기위7.9개월。결과 PVR발생솔:A조15.8%,B조45.5%,χ2검험,P<0.05。시망막탈리복발솔A조5.5%,B조33.3%,χ2검험,P<0.05。결론수술보이구내연합용약가유효억제술후PVR재형성,강저시망막탈리복발솔。
Objective To observe the suppressive effect of combination of tissue plasminogen activator(t-PA),heparin and homoharringtonine on the formation of proliferative vitreoretinopathy (PVR) after vitreoretinal surgery. Methods Forty-three cases (44 eyes)of complicated retinal detachment who received vitreoretinal surgery were divided into 2 groups.Twenty cases(20 eyes)in group A were treated by intravitreal injection of above mentioned drugs at the end of operation,while no intraocular injection of drugs given in 23cases(24 eyes)in group B.The mean follow-up period was 7.9 months. Result The rate of recurrent PVR in group A was 15.8%(3 of 19),and 45.5%(10 of 22) in group B (P<0.05).The rate of recurrent retinal detachment was 5.5%(1 of 18) in group A,and 33.3%(7 of 21) in group B,in group B (P<0.05). Conclusion Combination use of the above mentioned drugs can effectively suppress the postoperative recurrent PVR and lower the rate of subsequent recurrent retinal detachment.